Latest filing published 08 Aug 2019 for ReShape Lifesciences Inc., €18k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Mark Brister: trading record in brief
Mark Brister discloses dealings in 2 companies, chiefly ReShape Lifesciences Inc. and Dexcom Inc. Between 2 May 2006 and 6 August 2019, the trades on record add up to 7 filings.
Both buying and selling appear: 1 purchase worth €18k, against 1 sale worth €951k. On balance, insiders were net sellers of €933k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants. So far in 2019, the count stands at 1 purchase and no sales.
On 8 August 2019 came the latest disclosure, an open-market purchase for €18k in ReShape Lifesciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Mark Brister
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$4.009.2% of flowCommon StockSEC:0001214659-19-005092:0Canonical exit: 4 Nov 2019 (T+90)
- 107,142 shares@ US$1.8282.3% of flowCommon StockSEC:0001214659-18-005741:0
- 2,622 shares@ US$3.273.3% of flowCommon StockSEC:0001214659-18-003243:0
- 65,000 shares0Common Stock (Restricted Stock Award)SEC:0001214659-18-000185:0
- 1,860 shares@ US$7.175.2% of flowCommon StockSEC:0001214659-17-006341:0
- 1,550 shares@ US$9.035.9% of flowCommon StockSEC:0001214659-17-002940:0
- 50,000 shares@ US$24.00Common StockSEC:0001005477-06-002510:0
7 of 7 declarations
